文献速递血栓与止血

体重调整达肝素用于90公斤以上急性肿瘤相关静脉血栓栓塞患者的多中心前瞻性队列研究——WAVe研究

A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism-The WAVe Study.
PubMed 文献 · Am J Hematol · 2025-11-10

WAVe研究为多中心前瞻性队列研究,纳入91例体重超过90公斤的急性肿瘤相关血栓成年患者,接受体重调整达肝素200 IU/kg/日(最高33000 IU)治疗30(±4)天。30天主要出血累积发生率为5.3%(95%CI 1.1%-14.8%),复发性静脉血栓栓塞为1.2%(95%CI 0.1%-5.7%)。30天内出血事件者第7天谷值抗Xa水平中位数高于无出血者(0.6 vs. 0.2 IU/mL,p=0.01)。

要点

  • 体重超过90公斤的急性肿瘤相关血栓患者接受体重调整达肝素200 IU/kg/日(最高33000 IU),30天主要出血累积发生率为5.3%。
  • 30天复发性静脉血栓栓塞累积发生率为1.2%(95%CI 0.1%-5.7%)。
  • 30天内出血事件者第7天谷值抗Xa水平中位数高于无出血者(0.6 vs. 0.2 IU/mL,p=0.01)。

核心结论

  • 体重调整达肝素用于体重超过90公斤的急性肿瘤相关血栓患者与可接受的出血和血栓发生率相关。

研究设计与样本

  • 多中心前瞻性队列研究,纳入91例体重超过90公斤的急性肿瘤相关血栓成年患者(≥18岁),因招募困难提前终止。
  • 患者接受体重调整达肝素200 IU/kg/日(最高33000 IU)治疗30(±4)天,此后由临床医生决定继续抗凝并随访6个月。
  • 主要结局为30天主要出血,次要结局包括30天经客观确认的复发性静脉血栓栓塞和谷值抗Xa水平,采用竞争风险时间事件分析估计累积发生率。

主要发现

  • 中位体重为107.5公斤,达肝素中位日剂量为22500 IU。
  • 30天主要出血累积发生率为5.3%(95%CI 1.1%-14.8%),共3例患者发生主要出血。
  • 30天复发性静脉血栓栓塞累积发生率为1.2%(95%CI 0.1%-5.7%),共1例患者发生复发性静脉血栓栓塞。
  • 基于谷值抗Xa水平,至第30天未观察到显著生物蓄积。
  • 30天内出血事件者第7天谷值抗Xa水平中位数高于无出血事件者(0.6 vs. 0.2 IU/mL,p=0.01)。

局限性

  • 研究因招募困难在纳入91例患者后提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with cancer-associated thrombosis (CAT) are commonly treated with low-molecular-weight heparin (LMWH), but whether dose capping is needed in patients over 90 kg is unclear. We conducted the WAVe study, a multicenter prospective cohort study in adult patients (≥ 18 years) with acute CAT and a weight of over 90 kg starting anticoagulation. Patients received weight-adjusted dalteparin at 200 IU/kg per day (up to 33 000 IU) for 30 (± 4) days, after which anticoagulation was continued per clinician discretion and followed for 6 months. The primary outcome was major bleeding (MB) at 30 days. Secondary outcomes included objectively confirmed recurrent venous thromboembolism (VTE) at 30 days and trough anti-Xa levels. The cumulative incidences of outcomes were estimated by time-to-event analysis, with death as a competing risk. The study stopped early due to recruitment challenges after 91 patients. Median weight and daily dose of dalteparin were 107.5 kg and 22 500 IU, respectively. Three patients had a MB episode for a cumulative incidence of 5.3% (95% CI 1.1%-14.8%) at 30 days. One patient had recurrent VTE for a cumulative incidence of 1.2% (95% CI 0.1%-5.7%) at 30 days. No significant bioaccumulation noted up to Day 30 based on trough anti-Xa levels. The median Day 7 trough anti-Xa levels were higher in those with bleeding events within 30 days compared to those without (0.6 vs. 0.2 IU/mL, p = 0.01). Our results suggest that weight-adjusted dosing of dalteparin in patients over 90 kg is associated with acceptable rates of bleeding and thrombosis. Trial Registration: NCT03297359.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wang TF, Yeo E, Gross PL, et al. A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism-The WAVe Study. Am J Hematol. 2025. PMID: 41211763. doi:10.1002/ajh.70127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。